Head of the Institute

Prof. Dr. Matthias Schwab

Major Projects

  • Pharmacogenomics / Epigenetics of drug metabolizing enzymes, drug transporters and nuclear receptors  
  • Pharmacogenomics of anticancer and immunosuppressive drugs
  • Drug Interaction
  • Pediatric clinical pharmacology
  • Novel methodologies in genomic research and molecular diagnostics


Curriculum Vitae

Education and Professional Career


Coopted Professor at the faculty of mathematics and natural sciences - department of pharmacy and biochemistry, University of Tuebingen


Offer as Full Professor and Chair for Clinical Pharmacology, Karolinska University, Sweden in combination with a clinical position as Senior Physician at Karolinska University Hospital

2007 - present

Professor and Chair of Clinical Pharmacology, Eberhard Karl University Tuebingen, Germany

Head of the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and the Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tuebingen


Offer as Full Professor and Chair for Clinical Pharmacology, Medical University Innsbruck, Austria

2005 - 2006

Visiting Professor, St. Jude Children’s Research Hospital, Department of Pharmaceutical Sciences, Memphis, Tennessee, USA (Prof. W.E. Evans)


Habilitation for „Clinical Pharmacology and Paediatric Pharmacology“ at the Eberhard-Karls University Tuebingen

2001 - 2005

Senior physician and Head of the Research Unit for Clinical Trials and Drug Information Centre at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum)

2000 - 2005

Coordinator of the research focus "Pharmacogenetics" at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum)


Board Certification: Clinical Pharmacology


Board Certification: Paediatrics and Adolescent Medicine

Special qualification as emergency physician for newborns (acc to DÖGNPI), education for paediatric nephrology, additional certification in: Paediatric ultrasonography of the thyroid gland of head and neck, of the gastrointestinal tract and of female genitals, certification in addiction medicine in children and adolescents, certification in radiological diagnostics for thoracic organs, certification in basic psychosomatic medicine

1995 - 2001

Fellow in clinical pharmacology at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum)

1993 - 1995

Senior house officer at the University Hospital of Children and Adolescents, Friedrich-Alexander University of Erlangen-Nuernberg, Erlangen, Germany (Prof. Dr. C. Stehr)


State Licence as medical doctor


Doctor`s degree of medicine, Institute of Toxicology and Pharmacology, University Erlangen Nuernberg (Prof. Dr. R. Böcker / Prof. Dr. C. Estler).

1990 - 1993

Civilian service as house officer and later as senior house officer at the Children's Hospital, Nuernberg, Germany (Prof. Dr. H. Gröbe)

1983 - 1990

Study of medicine, Friedrich-Alexander University of Erlangen-Nuernberg

Appointments and Elected Offices

  • Academy of Science and Literature Mainz, Germany. Commission for Medical Research (2014-present, chair since 2015)
  • Baden-Wuerttemberg-International, Germany. Elected Committee for the joint partnership between BW and Kanagawa (Japan) “Technologies in an aging society”, Yokohama (2015)
  • European Assocation of Clinical Pharmacology and Therapy (EACPT) Council of EACPT (2010-2019), Executive Committee (2010-2017), Delegate to the Council (2020 - present)
  • European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) . EFLM-ESPT working group on Personalized Laboratory Medicine (WG-PLM) (2012-present)
  • European Health Foundation (EHF) . Board of Trustees (2013-2018)
  • European Medicines Agency (EMEA) . CPMP Pediatric Expert Group (PEG): Extraordinary member (2001-2004)
  • German Diabetes Association (DDG). Scientific Advisory Board “AG Molekularbiologie und Genetik des Diabetes mellitus“ (2017-present)
  • German Federal Institute of Drugs and Medicinal Products (BfArM) . Expert Group "Drugs for Children and Adolescents" according to AMG (2004-present: Full Member, and Vice Chair), Member of the Scientific Advisory Board (01/2022-12/2025)
  • German Medical Association (AkdÄ) . Drug Therapy Safety Commission. (Arzneimitteltherapie-sicherheit in Deutschland (AMTS)) (2007-present)
  • German Morbus Crohn/Colitis Ulcerosa Association DCCV e.V. Scientific Advisory Board (2014-2022)
  • German Society of Child and Adolescent Medicine. Committee of Drug Safety (KASK) (1998-present)
  • German Society of Clinical Pharmacology (DGKliPha) . Chair (2013-2018), Boardmember (2019-present)
  • German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT) . President (2015, 2018)
  • Institute of Digital Medicine (IDM Foundation) Stuttgart. Executive Board (2011-2013), Board of trustees (2013-2017)
  • Interfaculty Centre of Pharmacogenomics and Drug Research (ICEPHA) , Tübingen-Stuttgart. Scientific Board, Vice Chair, and Chair (2006-present)
  • International Union of Basic and Clinical Pharmacology (IUPHAR) . Sub-Committee Pharmacogenetics (2008-present), Sub-Committee Drug Metabolism and Transporter (2010-2014 Executive Board, 2014-2018 Vice Chair, 2019-2022 Chair)
  • Sub-Committee Pharmacogenetics, Drug Metabolism and Transport (2023 – present, Member)
  • Robert Bosch Stiftung, Stuttgart, Germany. Selection Committee „Fast Track – Exzellenz und Führungskompetenz für Wissenschaftlerinnen auf der Überholspur“ (2011, 2015, 2017)
  • University of Helsinki. International Evaluation Board of the Election of the Erkko Professorship (2014, 2017)
  • Verbund Klinische Pharmakologie in Deutschland e.V. Chair of the 17th Annual Meeting 2016 and of the 18th Annual Meeting 2017
  • Vienna Science and Technology Fund, Vienna, Austria. International Evaluation Board of Life Sciences Call 2016 Personalised Medicine (2015-2016)
  • Scientific Advisory Board, Reference Institute for Bioanalytics (Foundation for Pathobiochemistry and Molecular Diagnostics) , Bonn (2014-present)
  • Expert Group "HEXAL-Iinitiative drugs for children" (2004-2010)
  • Member of the expert advisory board of the Initiative Medicines for Children e.V. (IKAM) (2012-present)

Institutional Committees

Bosch Health Campus GmbH, Stuttgart, Germany

  • Research Council (1999-2005), Chair (2007- present)
  • Medical Council (2007-present)

Eberhard Karls University Tuebingen, Germany

  • Committee for Research Strategy & Coordination, Rektorat University Tübingen (2012- 2019)
  • Board of Members / Executive Board of the Comprehensive Cancer Center (CCC) University Hospital Tübingen (2009-present)
  • Council of the Medical Faculty University Tübingen (2010-present)
  • Extended Research Committee Med. Faculty University Tübingen (2008-2020)
  • Natural and Medical Sciences Institute (NMI, non-profit public-law foundation) Reutlingen, Germany, First Deputy Chairman (2010-present)
  • BMBF Excellence Strategy by the German Federal and State Governments Cluster of Excellence. Image-Guided and Functionally Instructed Tumor Therapies (iFIT), Member of the Steering Committee
  • NCT-Southwest, Director / Spokesman of the location Stuttgart
  • ZKS (Zentrum für Klinische Studien), Medical Faculty, University Tuebingen, Member of the Managing Board

Community Service / Ethical Committees

  • Committee for qualification as medical specialist in clinical pharmacology, Regional Medical Chamber Nordwürttemberg (2013-present)
  • Ethical Committee of the Medical Chamber of the State Baden-Württemberg (2004-present)
  • Ethical Committee of the University Hospital Tübingen (2017 - present)

Public (regional, federal) appointments

  • State Baden-Württemberg
    - Forum Gesundheitsstandort Baden-Württemberg (2018 – present)
  • Medical Chamber of the State Baden-Württemberg
    - Widerspruchsausschuss postgraduate training (2015-present)
    - Committee for qualification as medical specialist in clinical pharmacology, Regional Medical Chamber Nordwürttemberg (2013-present)
    - Regional Medical Chamber Südwürttemberg Member of the Commission for continuing education (Weiterbildungsausschuss) (2022 – 2027)
  • Federal German Ministry of Health, Berlin
    - Gendiagnostikkommission (2010-2013)
    - Committee of Experts on Drug Prescription (2013-present)
    - Expert committee for standard approvals (2017–2021)
  • Baden-Württemberg State Chamber of Pharmacists
    - Approval as a training center for the field of drug information (2023–2028)

Awards and Honors

  • Member of the Academia Europaea (2022)
  • Fellow of the British Pharmacological Society (2021)
  • Adjunct Professor for "Clinical Pharmacology" and "Biochemistry" at Yerevan State Medical University, Armenia (2018-2024)
  • Thomson Reuters/Clarivate Analytics Highly Cited Researchers, rubric “Pharmacology and Toxicology”/ "Cross Field" (2015/2016/2018/2021/2022/2023)
  • Robert-Pfleger Research Award (2016)
  • Conferment of the “Staufer-Medal” by the Prime Minister of Baden Württemberg (2015)
  • Celebratory Speech ("Vom Wert der Arznei - Wege zu einer zielgerichteten Therapie") at the Annual Meeting of the Academy of Science and Literature, Mainz, Germany (2014)
  • Member of the German National Academy of Sciences ‘Leopoldina’ (2014)
  • Most cited German pharmacologist in Europe (LabTimes, 2013)
  • Member of Faculty of 1000 Prime, Section Pharmacogenomics (2012-2016)
  • Full Member of the Academy of Science and Literature, Mainz, Germany (2012)
  • Authorization of IKP (M. Schwab) as a training center for ‘Drug information’ by the Chamber of Pharmacists of the State Baden-Württemberg (2010, renewal 2023 - 2028)
  • EACPT Key lecture “Personalized Medicine beyond Pharmacogenetics”, 16th World Congress on Basic and Clinical Pharmacology, Copenhagen, Denmark (2010)
  • Most cited pharmacologist in German-speaking countries (Laborjournal, 2009)
  • Galenus von Pergamon Award (2005)
  • Friedrich Hartmut Dost Award (2004)
  • Scholarship according to the "Bayerischen Begabtenförderungsgesetz" (1983-1990)

Scientific Journal Editorial Board Memberships

Editor in Chief

  • Pharmacogenetics & Genomics
  • Drug Research

Section Editor

  • "Pharmacogenomics and Personalized Medicine" of Genome Medicine
  • Monatsschrift Kinderheilkunde, Section Editor „Drug Therapy” (2015-2019)
  • • Journal of Personalized Medicine, Editor of Special Issue "Personalized Medicine Based on Drug Transporter Genetic Heterogeneity" (2019)

Editorial Boards

  • British Journal of Clinical Pharmacology, Member of the International Editorial Board (2013-present)
  • Clinical Chemistry (2008-2014)
  • Therapeutic Drug Monitoring (2010-present)
  • Journal of Personalized Medicine (2015-present)
  • Biomedicine Hub (2017-2019)
  • Clinical Pharmacology & Therapeutics (2020-present)

Book Editor

  • Cascorbi I, Schwab M. Prescision Medicine. Handbook of Experimental Pharmacology, vol 280. Springer, Cham, 2023
  • Kiess W., Schwab M., van den Anker J. (eds) Pediatric Pharmacotherapy. Handbook of Experimental Pharmacology, vol 261. Springer, Cham, 2020
  • Schwab M, Kaschka WP, Spina E (eds.). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 25. Karger, 2010
  • Seyberth WH, Rane A, Schwab M (eds.). Handbook of Experimental Pharmacology. Pediatric Clinical Pharmacology, 14th Edition, Springer, 2011

Applicant or Member of National and International Research Consortia (selection)

  • BMBF Excellence Strategy by the German Federal and State Governments Cluster of Excellence. Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
  • BMBF Virtual Liver Network
  • BMBF HepatoSys Network
  • BMBF LiSym Network
  • DFG Excellence cluster EXC 2180  Individualisierung von Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung therapeutischer Zielstrukturen iFIT
  • DFG Der Einsatz von Spatial Transcriptomics zum besseren Verständnis der Tumor-Heterogenität für die Prognose und die Therapieresistenz beim Nierenzellkarzinomspatial (Schwab – Schaeffeler)
  • DFG Graduiertenkolleg: "Nicht-kanonische G-Protein-abhängige Signalwege: Mechanismen, Funktionen, Konsequenzen"
  • DFG KFO 274 Thrombozyten - Molekulare Mechanismen und translationale Bedeutung, University of Tuebingen, Germany
  • DFG German-African Cooperation Projects in Infectious diseases, University Hospital Tuebingen, Germany
  • EU CONNECT4Children (IMI2 call 2017), European Paediatric Clinical Trials Network (c4c)
  • EU Horizon 2020 IMI2, Connecting digital mobility assessment to clinical out-comes for regulatory and clinical endorsement (MOBILISE-D)
  • GANI_MED (Greifswald Approach to Individualized Medicine), German Federal Ministry for Education and Research (BMBF)
  • German Center for Infection and Research (Dt. Zentrum für Infektionsforschung, IZF)
  • German Consortium for Translational Cancer Research (Dt. Konsortium für Translationale Krebsforschung, DKTK)
  • International Clinical Pharmacogenetics Implementation Consortium (Member, USA)
  • International Clopidogrel Consortium (Member of Steering Committee, Baltimore, USA)
  • International PGx nomenclature working group (USA- Centers for Disease Control and Prevention)
  • International TPMT nomenclature committee (
  • Kinacept consortium: Novel anti-inflammatory compounds for autoimmune diseases (FP7-SME-1)
  • NeuRoSIS-Consortium: Efficacy and Safety of Inhaled Budesonide in very Preterm Infants at risk for Bronchiopulmonary Dysplasia (FP5 Health 2009)
  • PREDICT: Holistic Multi-Scale Modeling of Targeted Protein Therapeutics Action: Towards Predicting Effective Treatment of Cancer (BMBF)
  • SFB 685 “Immunotherapy: Molecular Basis and Clinical Application”, University of Tuebingen, Germany
  • The Pharmacogene Variation (PharmVar) Consortium, Kansas City, USA
  • U-PGx consortium: Making actionable pharmacogenomics data and effective treatment optimization accessible to every European citizen“(EU, Horizon 2020)
  • Verbundprojekt FORSYS-Kooperation „Ein systembiologischer Ansatz zur prädiktiven Krebstherapie“ (BMBF)
  • Verbundprojekt INFORM „Individualized Therapy for Relapsed Malignancies in Childhood“, Deutsche Krebshilfe e.V. (Deutsche Kinderkrebsstiftung, DKTK)

Coordinator of Training Sites and Research Networks (national / international) including sections

  • EU FP7-People-ITN: Marie Curie Initial Training Network “Fighting Drug´Failure”. Lead Applicant and Consortium heads: Schwab M & Brauch H
  • EU CONECT4Children (IMI2 call 2017: European Paediatric Clinical Trials Network, M. Schwab, German Coordinator)
  • U-PGx consortium: Making actionable pharmacogenomics data and effective treatment optimization accessible to every European citizen“(EU, Horizon 2020, M. Schwab, Vice Chair)
  • BMBF (01ZP0502): Open label, prospective, observational, multi-centre trial in postmenopausal, hormonereceptor positive breast cancer patients treated with either tamoxifen or an aromatase inhibitor (IKP211). Study PI (since 2007)
  • ICEPHA Minigraduate College Membrane associated drug targets in Oncology
  • BMBF Verbundprojekt “Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients (TAMENDOX)

Member of Professional Bodies

  • International Society of the Study of Xenobiotics (ISSX)
  • American Society for Clinical Pharmacology and Therapeutics (ASCPT)
  • European Association of Clinical Pharmacology and Therapeutics (EACPT)
  • European Society for Developmental, Perinatal & Pediatric Pharmacology (ESDPPP)
  • German Society of Clinical and Experimental Pharmacology (DGPT)
  • German Society of Child and Adolescent Medicine (DGKJ)
  • German Society of Nephrology (GPN)
  • German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL)
  • Deutsche Morbus Crohn / Colitis Ulcerosa Vereinigung e.V. (DCCV)